Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts

Journal of Hypertension

Volumn 30, Issue 10, 2012, Pages 1928-1936

  Sehestedt, Thomas ^a,b   Jeppesen, Jørgen ^a,c   Hansen, Tine W ^b,d   Rasmussen, Susanne ^e   Wachtell, Kristian ^e   Ibsen, Hans ^f   Torp Pedersen, Christian ^c,e   Olsen, Michael H ^c,g  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Research Center for Prevention and Health   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Rigshospitalet   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f HOLBÆK HOSPITAL   (Denmark)

^g ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cardiovascular risk; Framingham; Left ventricular mass index; pulse wave velocity; SCORE; subclinical organ damage; thresholds; urine albumin creatinine ratio

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; DEATH; EUROPEAN SOCIETY OF CARDIOLOGY RISK CHART; EUROPEAN SOCIETY OF HYPERTENSION RISK CHART; FEMALE; FRAMINGHAM RISK SCORE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEMODYNAMIC PARAMETERS; HUMAN; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR MASS INDEX; MAJOR CLINICAL STUDY; MALE; NONFATAL MYOCARDIAL INFARCTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; PULSE WAVE; RENAL SYSTEM PARAMETERS; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK; URINE ALBUMIN CREATININE RATIO;

EID: 84866551261     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328356c579     Document Type: Article

References (32)

1. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the 'only-50%' myth. Arch Intern Med 2001; 161:2657-2660.
2. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282:2012-2018.
3. Law MR, Wald NJ, Morris JK. The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. J Med Screen 2004; 11:3-7.
4. Mancia G, De BG, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
5. National Kidney Foundation. Part 4. Definition and classification of stages of chronic kidney disease. Am Kidney Dis 2002; 39(2, Suppl 1): S46-S75.
6. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
7. Laurent S, Cockcroft J, Van BL, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
8. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898-903.
9. Matsushita K, van d V, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
10. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Rasmussen S, Thijs L, Ibsen H, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113:664-670.
11. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 1988; 108:7-13.
12. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
13. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
14. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117:743-753.
15. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27:157-172.
16. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355:2631-2639.
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echo-cardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
18. Rowe DJ, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27 (Pt 4):297-312.
19. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003; 56:124-130.
20. Volpe M, Battistoni A, Tocci G, Rosei EA, Catapano AL, Coppo R, et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens 2012; 30:1056-1064.
21. Peters SA, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012; 98:177-184.
22. Greenland P. Improving risk of coronary heart disease: can a picture make the difference? JAMA 2003; 289:2270-2272.
23. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. Eur Heart J 2010; 31:2338-2350.
24. Hillege HL, Fidler V, Diercks GF, van Gilst WH, De ZD, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
25. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
26. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
27. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.
28. WeberT, Ammer M, Rammer M, Adji A, O'Rourke MF, Wassertheurer S, et al. Noninvasive determination of carotid-femoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 2009; 27:1624-1630.
29. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De BD, et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension 2010; 56:91-98.
30. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, Wachtell K, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007; 28:1374-1381.
31. Asmar R, Benetos A, Topouchian J, Laurent P, Pannier B, Brisac AM, et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement. Validation and clinical application studies. Hypertension 1995; 26:485-490.
32. Thomsen TF, McGee D, Davidsen M, Jorgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002; 31:817-822.